Titlebook: Metronomic Chemotherapy; Pharmacology and Cli Guido Bocci,Giulio Francia Book 2014 The Editor(s) (if applicable) and The Author(s), under e

噱頭

Mechanisms of Action of Low-Dose Metronomic Chemotherapygs in low doses. This relatively new treatment strategy concept is called low-dose metronomic (LDM) chemotherapy. The therapeutic efficacy of LDM has been assessed for reducing the tumor load during the acute phase and in delaying relapse during the maintenance phase. The major benefits found in usi

腐蝕

Effects of Metronomic Chemotherapy on Immunityincluding immune cells. Therefore, conventional and maximum-tolerated dose chemotherapy is inevitably associated with the risk of immunity deterioration. Metronomic chemotherapy is a unique protocol that administers chemotherapeutic agents at relatively low doses, without prolonged drug-free periods

Morphine

蛤肉

Metronomic Chemotherapy Regimens Using Microtubule-Targeting Agents: Mechanisms of Action, Preclinicers. Although originally administered at or close to the maximum tolerated dose once every 3 weeks, the discovery of their potent antiangiogenic properties at the end of the 1990s has led to the re-evaluation of treatment protocols. Nowadays, MTAs are often administered at lower doses either weekly

Cpap155

Metronomic Chemotherapy in Breast Cancersme metastatic during the follow-up period and need a personalized and/or target treatment approach. Metronomic chemotherapy can be regarded as a multi-targeted therapy for advanced disease, combining effects not only on tumor cells but also on their microenvironment by inhibiting tumor angiogenesis,

木質(zhì)

helper-T-cells

Clinical Trials of Low-Dose Metronomic Chemotherapy in Castration-Resistant Prostate Cancerte cyclic treatment interruptions. Recently, LDM chemotherapy has gained traction for the treatment of castration-resistant prostate cancer (CRPC). Its excellent safety profile and relatively low rate of severe (i.e., grade 3/4) toxicities make it an enviable treatment, especially for elderly and fr

使饑餓

STRIA

Clinical Activity of Metronomic Chemotherapy in Central Nervous System Cancerscharacteristics in malignant gliomas is the robust and aberrant vasculature within the tumor which could be the target for the frequent administration of low-dose metronomic chemotherapy. This chapter will mainly focus on determining current status and recent trends of metronomic treatment for CNS t

GROUP

Metronomic Chemotherapy in Pediatric Malignanciesconventional chemotherapy.Several pediatric preclinical solid tumor modelsaresupportingthe clinical development of this newtherapeuticmodality in pediatriccancer. Maintenancelowdosechemotherapyhasproven itsbenefits in increasingoverallsurvival inseveral pediatric cancer. Thischapter isreviewingthecu